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LIGHT initiates intracellular signaling via engagement
of the two TNF receptors, HVEM and LTbR. In hu-
mans, LIGHT is neutralized by DcR3, a unique solu-
ble member of the TNFR superfamily, which tightly
binds LIGHT and inhibits its interactions with HVEM
and LTbR. DcR3 also neutralizes two other TNF li-
gands, FasL and TL1A. Due to its ability to neutralize
three distinct different ligands, DcR3 contributes to a
wide range of biological and pathological processes,
including cancer and autoimmune diseases. How-
ever, the mechanisms that support the broad speci-
ficity of DcR3 remain to be fully defined. We report
the structures of LIGHT and the LIGHT:DcR3 com-
plex, which reveal the structural basis for the DcR3-
mediated neutralization of LIGHT and afford insights
into DcR3 function and binding promiscuity. Based
on these structures, we designed LIGHT mutants
with altered affinities for DcR3 and HVEM, which
may represent mechanistically informative probe
reagents.
INTRODUCTION
Myriad interactions involving secreted and cell surface proteins
provide the stimulatory and inhibitory signals that determine
the course, strength, and duration of mammalian immune
responses. Members of the tumor necrosis factor/tumor necro-
sis factor receptor (TNF/TNFR) superfamilies make important
contribution to these processes (Cai and Freeman, 2009), and
these same molecules are associated with numerous autoim-
mune diseases. Furthermore, the associated signaling pathways
are co-opted by infectious agents and malignancies for evasion
of the host immune response. These properties make the mem-
bers of the TNF/TNFR superfamilies prime targets for a wide
range of immunotherapies involving function modulating mono-
clonal antibodies (mAbs) and multimeric soluble versions of
these molecules themselves. For example, Remicade, a mAb1252 Structure 22, 1252–1262, September 2, 2014 ª2014 Elsevier Ltagainst TNF, which results in blockade of the TNFR signaling
pathway by sequestration of TNF, is used to treat autoimmune
disorders such as rheumatoid arthritis, ulcerative colitis, and
Crohn’s disease. Enbrel is a soluble TNFR-immunoglobulin
(TNFR-Ig) fusion protein, formed from the extracellular domain
of TNFR and the Fc region of IgG1, which binds with high affinity
to TNF. This interaction prevents TNF from engaging and
activating cell-surface-associated TNFR, resulting in clinically
significant reductions in inflammatory responses in rheumatoid
arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic ar-
thritis, and ankylosing spondylitis (Bendtzen, 2012).
Due to their important roles in immunity, pathogenesis, and
clinical applications, the structures of these molecules and com-
plexes have been extensively studied. The TNF ligands are type
II integral membrane proteins that typically form compact
trimeric assemblies, in which each protomer adopts a beta sand-
wich ‘‘jelly-roll’’ structure (Eck and Sprang, 1989). TNF receptors
are type I membrane proteins containing one to six cysteine-rich
domains (CRDs), which bind to the interprotomer interface
formed between adjacent TNF ligand monomers (Tansey and
Szymkowski, 2009). These interactions typically result in hex-
americ assemblies, with 3:3 (or sometimes 2:3) receptor:ligand
stoichiometries, which span interacting cells. The ligand-medi-
ated clustering of TNFRs triggers the recruitment of adaptor
proteins, such as death domain adaptor proteins and TNFR-
associated factors (TRAFs), which control diverse downstream
signaling pathways (Ashkenazi, 2002).
LIGHT (homologous to lymphotoxin, exhibits inducible expres-
sion and competeswithHSV glycoprotein D for herpesvirus entry
mediator, a receptor expressed on T cells) is a member of the
TNF superfamily that is transiently induced on activated T cells
(Mauri et al., 1998). LIGHT is recognized by two differentially ex-
pressed TNFR superfamily members, herpes simplex virus entry
mediator (HVEM) and lymphotoxin beta receptor (LTbR) (Mauri
et al., 1998; Zhai et al., 1998). LIGHT functions as part of a
costimulatory circuit to boost T cell proliferation and cytokine
production through its interaction with HVEM (Tamada et al.,
2000; Zhai et al., 1998). Blockade of LIGHT signaling by
HVEM-Ig and LTbR-Ig fusion proteins dramatically reduces
T cell proliferation and cytotoxic T cell activity (Tamada et al.,
2000; Wang et al., 2001). Furthermore, constitutive expression
of LIGHT on T cells in transgenic mouse models results ind All rights reserved
Figure 1. The Interaction Network of LIGHT and DcR3 within the
TNF/TNFR Superfamilies
TNF ligands FasL (orange), LIGHT (blue), and TL1A (magenta) bind to Fas (light
orange), DR3 (dark magenta), and HVEM (green) and LTbR (dark blue),
respectively, transducing proliferative (+) or apoptotic () signals to different
cell types. Engagement of TL1A with DR3 expressed on T cells promotes
proliferation, whereas interaction of TL1A with DR3 expressed on osteoblasts
induces apoptosis. The signals transduced by FasL, LIGHT, and TL1A can all
be blocked by DcR3 (red), which competes for binding with the cognate
signaling receptors.
See also Figure S7.
Structure
Structures of LIGHT and LIGHT:DcR3 Complexabnormal T cell activation, leading to diverse autoimmune re-
sponses and severe inflammation in the gut (Shaikh et al.,
2001; Wang et al., 2001).
In contrast to the expression of HVEM on lymphocytes, LTbR
is widely expressed on epithelial, stromal, and myeloid cells but
not lymphocytes, which is consistent with a role in mediating sig-
nals between lymphocytes and nearby epithelial and stromal
cells (Ware, 2005). Engagement of LIGHT by LTbR initiates
multiple signaling pathways, including JNK/c-Jun and NF-kB
activation (Chang et al., 2002; Kim et al., 2005). LTbR signaling
in intestinal epithelial cells elicits a protective response against
mucosal bacterial C. rodentium infection (Wang et al., 2010).
Signaling through LTbR initiated by soluble LIGHT induces cell
death of certain tumor cell lines such as HT-29 and MDA-MB-
231 (Browning et al., 1996; Rooney et al., 2000; Yu et al., 1999;
Zhai et al., 1998).
Human LIGHT also binds decoy receptor 3 (DcR3; also
referred to as TNFRSF6B), which contains four CRDs at its N ter-
minus and an approximately 100-residue C-terminal segment
that binds heparan sulfate proteoglycans (HSPG) (Zhan et al.,
2011). Unlike other members of the TNFR superfamily, which
are cellular receptors capable of transducing signals, DcR3 lacks
transmembrane and cytoplasmic segments, resulting in a solu-
ble secreted molecule capable of interacting with multiple cell
types (Connor et al., 2012; You et al., 2008; Zhan et al., 2011).
DcR3 exhibits broad specificity, recognizing three TNF ligands,
LIGHT, FasL, and TL1A, through canonical interactions involvingStructure 22, 1252–12the CRDs (Chang et al., 2006; Hsu et al., 2004; Zhan et al., 2011).
These interactions result in blockade of the associated signaling
pathways by virtue of interfering with recognition between the
TNF ligands and their cognate receptors.
Defining the precise contributions of DcR3 to adaptive and
innate immunity is challenging because of the diverse functions
of the three TNF ligands that it neutralizes (Figure 1). DcR3 dis-
rupts the activation signal initiated by LIGHT, resulting in
reduced T cell activation (Zhang et al., 2001). Inhibition of the
TL1A signaling pathway also downregulates the T cell immune
response and is a potential strategy for the treatment of autoim-
mune diseases (Young and Tovey, 2006). In contrast, blockade
of the Fas:FasL interaction, which induces T cell apoptosis and
restrains the immune response, may contribute to the develop-
ment of autoimmune disorders (Funke et al., 2009; Hayashi
et al., 2007). Systemic expression of human DcR3 in mice
(DcR3 is not present in mice, while LIGHT, TL1A, and FasL ortho-
logs are present in mice) attenuates the T cell immune response,
suggesting an overall negative role of DcR3 in the regulation of
the immune system (Hsu et al., 2005). Consistent with an atten-
uator role for DcR3, it has been demonstrated that DcR3 is
present at a low level in a wide range of tissues from healthy hu-
mans, while it is highly elevated in patients with cancer (Wu et al.,
2003). Tumor-secreted DcR3 functions as a decoy receptor for
FasL and LIGHT on lymphocytes to prevent transmission of
apoptotic signals via tumor-expressed Fas and LTbR, thus
providing a mechanism for immune evasion by the malignant
cells (Ashkenazi, 2002). The role of DcR3 is further complicated
by contributions of the C-terminal region, which was recently re-
ported to bind HSPG and trigger apoptosis of antigen-present-
ing cells (Chang et al., 2006; Hsu et al., 2004; You et al., 2008).
Despite the roles of LIGHT and DcR3 in regulating the immune
response (Figure 1), the structural basis of LIGHT and DcR3
engagement and function remains to be elucidated. Herein, we
report the biochemical and structural properties of LIGHT and
the LIGHT:DcR3 complex. These structures define the physical
determinants contributing to ligand-receptor recognition and
specificity, and they provide the basis for designing novel LIGHT
mutants with altered selectivities toward its multiple ligands. This
work shows the structural basis of DcR3-mediated neutralization
of LIGHT and enabled the design of molecules to antagonize and
probe DcR3 function.
RESULTS
Overall Structure of the LIGHT:DcR3 Complex
We determined the crystal structures of LIGHT and LIGHT in
complex with DcR3 (Table 1). Soluble LIGHT (residues L83–
V240, numbering from the initiation codon) crystallized with
one canonical TNF-like trimer in the asymmetric unit. The com-
plex between LIGHT and DcR3 (residues V30–S195) revealed
two 3:3 hetero-hexameric assemblies typical of the TNF and
TNFR superfamilies. We define the conventional binding inter-
face between LIGHT and DcR3 in the hexameric assembly as
the cis interaction interface and the interface between two hex-
americ assemblies as the trans interaction interface. Based
on the structure of the LIGHT:DcR3 complex, we designed two
mutants of LIGHT that retain approximately wild-type affinity
for DcR3 but have significantly reduced affinity for HVEM.62, September 2, 2014 ª2014 Elsevier Ltd All rights reserved 1253
Table 1. Data Collection and Refinement Statistics
LIGHT LIGHT:DcR3 LIGHT Mutant 2 Mutant1:DcR 3 Mutant2:DcR 3
Data Collection
Wavelength used (A˚) 0.9791 1.075 1.075 1.075 1.075
Resolution range (A˚) 2.59–50.00 2.40–50.00 2.25–50.00 2.27–50.00 2.78–50.00
Space group I212121 P213 P21 P213 P213
Unit cell (A˚) a = 94.7, b = 100.0,
c = 124.4
a = b = c = 149.1 a = 59.6, b = 46.9,
c = 70.4
a = b = c = 149.3 a = b = c = 148.8
Unit cell () b = 98.02
Unique reflections (N) 18,664 43,288 18,578 51,516 27,912
Redundancy 7.8 (8.1) 11.2 (11.2) 7.3 (7.1) 11.6 (11.3) 12.5 (12.8)
Completeness 100(100) 100(100) 100(99.5) 100(100) 99.9(100)
I/s 7.3 (2.0) 27.2 (3.5) 24.7 (4.7) 23.1 (4.4) 20.1 (4.1)
Rmerge
a 0.136 (0.950) 0.102 (0.810) 0.079 (0.448) 0.104 (0.650) 0.140 (0.691)
Refinement
Resolution range (A˚) 2.59–46.12 2.40–19.93 2.25–20.00 2.27–37.35 2.78–49.63
Rwork
b 0.234 (0.350) 0.194 (0.277) 0.211 (0.244) 0.195 (0.237) 0.178 (0.266)
Rfree 0.286 (0.410) 0.232 (0.292) 0.286 (0.339) 0.238 (0.292) 0.235 (0.356)
Average B factor (A˚2) 74 41 41 46 45
Rms bond (A˚) 0.004 0.018 0.015 0.023 0.017
Rms angles () 1.274 1.961 1.885 2.099 1.983
PDB code 4EN0 4J6G 4KG8 4KGQ 4KGG
Parentheses indicate statistics for the highest resolution bin. Rms, root-mean-square.
aRmerge = ShklSijIi(hkl)  < I(hkl) > j/ ShklSiIi(hkl).
bRwork = SjFc  Foj/SFo.
Structure
Structures of LIGHT and LIGHT:DcR3 ComplexConsideration of all local and crystallographic symmetry opera-
tors results in an unusual dodecameric structure formed by
the intimate packing of the two conventional heterohexameric
assemblies in the crystal (Figure S1 available online).
The Conventional Binding Interface between LIGHT
and DcR3
The asymmetric unit of the LIGHT:DcR3 crystal structure con-
sists of two independent chains of LIGHT and two independent
chains of DcR3 that, on application of crystallographic 3-fold
rotational operators, form two canonical 3-fold symmetric
TNF:TNFR heterohexameric assemblies. The two heterohex-
amers are related to each other by a noncrystallographic 2-fold
rotational operator perpendicular to the crystallographic 3-fold
axis. LIGHT adopts the typical jelly-roll fold of the TNF family
(Eck and Sprang, 1989), with the inner and outer beta-sheets
composed of strands A0AHCF and B0BGDE, respectively (Fig-
ure S2). Each DcR3 molecule contacts the surface formed by
two adjacent LIGHT protomers, resulting in an assembly with
overall 3:3 receptor:ligand stoichiometry in which no direct con-
tacts occur between individual receptor molecules (Figure 2).
The two independent copies of LIGHT and DcR3 are highly
similar, with root-mean-square deviations (rmsds) of 0.2 A˚ (for
138 aligned LIGHT Ca atoms) and 0.9 A˚ (for 158 aligned DcR3
Ca atoms), respectively. The two independent heterohexamers
exhibit nearly identical binding interfaces with buried solvent-
accessible areas of 1,060 A˚2 for chains A (LIGHT) and C
(DcR3) and 1,020 A˚2 for chains B (LIGHT) and D (DcR3) (these
values refer to the buried surface area associated with a single
DcR3 chain interacting with the LIGHT trimer). All subsequent1254 Structure 22, 1252–1262, September 2, 2014 ª2014 Elsevier Ltdiscussions are based on the structure of the complex formed
by chain A (LIGHT) and chain C (DcR3).
The LIGHT:DcR3 interface is largely formed by residues
contributed by the AA0, CD, DE, EF, and GH loops of LIGHT
and by CRD2 and CRD3 of DcR3 (Figure 2; Figure S2). The bind-
ing surface of LIGHT can be divided into two parts: the lower re-
gion proximal to the ligand-associated plasma membrane and
the upper region distal to the plasma membrane (Zhan et al.,
2011). Loops of AA0, DE, and GH in the lower region of LIGHT
contribute to the interaction with CRD2 of DcR3, while the CD
andEF loops in the upper region of LIGHT contactCRD3ofDcR3.
A number of ionic and hydrogen bonding interactions support
the contact between the lower region of LIGHT and DcR3, with
DE loop residues T170–E178 interacting with Y78–E86 and
R89 at the beginning and N92 in the middle of the DcR3 CRD2
(Figure 2). Polar interactions are formed by LIGHT DE loop resi-
dues R172, Y173, E175, E176, and E178 contacting Q80, Y84,
R89, and N92 of DcR3. Among these, Y173 is conserved in all
three DcR3 ligands: LIGHT, TL1A, and FasL (Zhan et al., 2009).
In the LIGHT:DcR3 structure, the side chain of Y173 extends
into a geometrically complementary cavity of DcR3 and forms
a hydrogen bond with the main chain amide nitrogen of DcR3
Q80 (Figure S3). The Y173F mutant of LIGHT exhibited sig-
nificantly decreased binding to its receptors HVEM and LTbR,
suggesting the general importance of this residue in receptor
recognition (Rooney et al., 2000). The main chain oxygen and a
side chain guanidinium nitrogen of LIGHT R172 form polar con-
tacts with the main chain amide nitrogen and oxygen of DcR3
Y84, respectively. The main chain oxygen of LIGHT E175 forms
a hydrogen bond with the side chain of DcR3 R89.d All rights reserved
Figure 2. Overall Structure and Determi-
nants of LIGHT: DcR3 Recognition
(A) Side view (top) and bottom view (bottom) of the
overall structure of LIGHT:DcR3 complex. LIGHT is
shown as a cartoon (blue and red), and DcR3 is
shown as surface (gray). One LIGHT homotrimer
binds three DcR3 molecules at interprotomer
interfaces.
(B) The GH loop (magenta) makes polar contacts
with DcR3 (gray and green).
(C) The DE loop (magenta) makes polar contacts
with DcR3 (gray and green).
See also Figure S3.
Structure
Structures of LIGHT and LIGHT:DcR3 ComplexAn additional patch of polar contacts is formed between the
GH loop of LIGHT and CRD2 of DcR3, with residues R226–
T231 of the GH loop interacting with residues N92–E99 in
DcR3CRD2 (Figure 2). Themain chain carbonyl oxygen of LIGHT
R228 forms a hydrogen bond with the amide nitrogen of DcR3
L94 (Figure 2). In addition, the side chain of LIGHT R228 forms
a salt bridge with the side chain of DcR3 E99. The main chain
carbonyl oxygen of LIGHT D229 also forms a hydrogen bond
with the side chain nitrogen of N92 (Figure 2). Notably, the LIGHT
R228E mutation resulted in a significant decrease in affinity for
HVEM but did not significantly affect the interaction with LTbR
(Chen et al., 2003). Although the GH loop appears important
for the interaction with DcR3, the residues in this region are not
conserved among LIGHT, TL1A, and FasL, suggesting that the
diversity of this loop may provide some of the specificity deter-
minants required for each ligand to recognize its own signaling
receptors while maintaining binding with DcR3.
Also of note are G100–N102 and E115–G119 of the AA0 loop of
LIGHT, which contact CRD2 of DcR3 at the binding interface.
The mutation of LIGHT residues E115–L120 significantly
reduced the affinity for DcR3, suggesting an important role of
this loop in recognition (Morishige et al., 2010).
The upper region of the interface accounts for approximately
40% of the total buried solvent-accessible area of LIGHT in the
conventional LIGHT:DcR3 binding interface, with the LIGHT
CD (G150–V152 and T161) and EF (R195–W198) loops inter-
acting with DcR3 CRD3 residues H122–L127. Hydrophobic in-
teractions play important roles, with F125 of DcR3 occupying a
hydrophobic pocket formed by LIGHT residues V152, V196,
and W198. The side chain of DcR3 L127 is also close to theStructure 22, 1252–1262, September 2, 2014same hydrophobic pocket on LIGHT.
The only observed polar contact in the up-
per region is the potential hydrogen bond
between the side chain indole nitrogen of
LIGHT W198 and the main chain oxygen
of DcR3 A123.
Comparison of LIGHT:DcR3 and
TL1A:DcR3 Complexes
The structures of the LIGHT:DcR3 and
TL1A:DcR3 complexes revealed gener-
ally similar interaction patterns between
the two ligands and DcR3 in the lower re-
gion, with analogous loops of LIGHT andTL1A contacting the same surfaces on DcR3. The interfaces in
the upper region of the LIGHT:DcR3 and TL1A:DcR3 complexes
are less similar, due to detailed conformational differences in
DcR3, although comparable areas on DcR3 contact analogous
loops in the ligands.
The AA0, DE, and GH loops of TL1A in the lower region interact
predominately with CRD2 of DcR3 in a manner similar to that of
LIGHT, with the DE loop also being one of the major determi-
nants contacting DcR3 (Figure 3). Multiple residues are involved
in polar contacts, including the side chains and/or main chains
of DcR3 Y78–E86. We previously hypothesized that the broad
specificity of DcR3 arises from the recognition of invariant back-
bone determinants and conserved side chains in the DE loops of
the three ligands (Zhan et al., 2011). Comparison of LIGHT:DcR3
and TL1A:DcR3 structures supports this notion. For example,
the side chain hydroxyls of TL1A Y188/LIGHT Y173 make polar
contacts with the main chain nitrogen of DcR3 Q80 (Figure S3;
the numbering for TL1A follows that found in UniProt entry
O95407, including the signal peptide sequence). Mutation of
TL1A Y188 severely compromised DcR3 binding, highlighting
the importance of this interaction (Zhan et al., 2009). The
carbonyl oxygen of TL1A S187 (analogous to LIGHT R172)
forms a hydrogen bond with the main chain amide of DcR3
Y84. The main chain carbonyl oxygens of TL1A E200 and
P201 (analogous to LIGHT E175 and E176) form potential
hydrogen bonds with a guanidinium nitrogen on the side chain
of DcR3 R89.
As observed in the LIGHT:DcR3 complex, additional interac-
tion determinants in the lower region of TL1A are contributed
by the AA0 and GH loops (Figure 3). Two separate segments ofª2014 Elsevier Ltd All rights reserved 1255
Figure 3. Comparison of the Structures of
the LIGHT:DcR3 and TL1A:DcR3 Complexes
Reveals Similar Interaction Determinants on
Both Ligand and Receptor
The upper and lower regions are separated by a
blue dashed line. The upper region of the interface
is colored blue. The DE loop of the lower region is
colored yellow, and the other parts of the lower
region are colored red.
(A) ‘‘Open-book’’ view of LIGHT:DcR3 binding
surfaces. The DcR3 molecule was rotated around
one axis by 180 to expose the binding interface.
(B) ‘‘Open-book’’ view of TL1A:DcR3 binding
surfaces.
(C) Alignment of the three DcR3 ligands LIGHT,
TL1A, and FasL shows less than 35% sequence
identity. The binding residues shaded red, yellow,
and blue in (A) and (B) are correspondingly
colored.
See also Figure S4.
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Structures of LIGHT and LIGHT:DcR3 ComplexTL1A in the AA0 loop (V101–R103 and E120–A126) and the tip of
the GH loop (Y238–E241) are buried at the interface with the end
of DcR3 CRD2 (Figure 3). Among these interactions, the main
chain carbonyl oxygen of TL1A T239 (analogous to LIGHT
R228) makes a hydrogen bond with the amide nitrogen of
DcR3 L94, while the side chain carbonyl oxygen of TL1A E241
forms a polar contact with the side chain amide nitrogen of
DcR3 N92 (Figure S4).
Although the interfaces involving the upper regions of TL1A
and LIGHT utilize similar surfaces, the detailed spatial organi-
zation of DcR3 in this region is distinct in the two complexes.
Structural superposition of the LIGHT:DcR3 and TL1A:DcR3
complexes, based on alignment of the LIGHT and TL1A ligands,
showed that most of DcR3 CRD2 aligns well (Figure S5) (Hase-
gawa and Holm, 2009). However, relative to the TL1A:DcR3
complex, when bound to LIGHT, the C-terminal portion of
DcR3 is shifted (15), resulting in a more angular DcR3 archi-
tecture and a different spatial organization of the upper binding
regions (Figure S5). This variation results from distinct interac-
tions in the upper region; LIGHT binds to DcR3 mainly through
hydrophobic interactions, while TL1A utilizes polar contacts.
For example, G150–V152 of LIGHT, which contributes to this
interface (discussed earlier), has no polar contacts with DcR3.
In contrast, residue TL1A R156 (analogous to LIGHT G150) con-
tacts the main chain oxygen of G124 on DcR3 through a side
chain guanidinium nitrogen.
DcR3 Responsiveness of LIGHT
The asymmetric unit of the LIGHT crystals contains a tightly
packed trimeric assembly typical of TNF ligands. Each protomer
buries 2,130 A˚2 of solvent-accessible surface area in the trimer,
similar to that observed in TL1A (1,960 A˚2; Protein Data Bank
[PDB] entry 2QE3) and other TNF ligands (TNF alpha, 2,370 A˚2,
PDB entry 1TNF; lymphotoxin alpha, 1,950 A˚2, PDB entry1256 Structure 22, 1252–1262, September 2, 2014 ª2014 Elsevier Ltd All rights reserved1TNR; TRAIL, 2,180 A˚2, PDB entry
1D2Q). Light scattering analysis revealed
an apparent molecular weight of 55 kDa,
consistent with the calculated molecularweight (52 kDa) of trimeric LIGHT (Figure S6). Superposition of
the receptor-free LIGHT and TL1A (PDB entry 2QE3) monomers
shows a similar overall scaffold with an rmsd of 1.4 A˚ for 124
structurally equivalent Ca atoms and an rmsd of 1.5 A˚ for super-
position of the intact trimers (Figure S2). DcR3-bound and -un-
bound LIGHT are similar, with an rmsd of 1.0 A˚ for 138 aligned
Ca atoms (Figure 4). The largest deviations are located in loops
involved in contacting DcR3, suggesting that these segments
of LIGHT are conformationally responsive to receptor engage-
ment. The most significant structural alterations involve T170–
E178 in the DE loop, G100–N102 in the AA0 loop and R226–
T231 in the GH loop (Figure 4). Significant DcR3-dependent
structural changes were also observed in the analogous loops
in TL1A (Zhan et al., 2011).
Loop Transplant from TL1A to LIGHT
Comparison of the TL1A:DcR3 and LIGHT:DcR3 complexes
indicates that TL1A and LIGHT use similar strategies for recogni-
tion of the same surfaces on DcR3; however, the DcR3 recogni-
tion loops in the ligands share low sequence identity (Figure 3).
These same segments in LIGHT and TL1A confer binding spec-
ificities for their cognate signaling receptors (i.e., DR3 for TL1A;
HVEM and LTbR for LIGHT). Based on these observations, we
hypothesized that transplantation of loops from TL1A to the cor-
responding region of LIGHT might result in LIGHT mutants pos-
sessing wild-type affinity for DcR3 and reduced affinity for the
signaling receptors of LIGHT (Figure 5).
Loops from both the lower (GH loops, residues R226–T231)
and upper (EF loops, residues R195–W198) regions of TL1A
were selected for transplantation into LIGHT and designated
as mutant 1 and mutant 2, respectively (Table 2; Figure S5).
The chimeric proteins were expressed in E. coli and exhibited
apparent molecular weights similar to those of wild-type
LIGHT, as determined by size exclusion chromatography
Figure 4. DcR3-Dependent Conformational
Changes of LIGHT
(A) Zoom-in view of the DE loop shows significant
DcR3-dependent structural alterations.
(B) Superposition of LIGHT unbound (green) or
bound (magenta) with DcR3 shows slight
changes in the two parallel beta-sheets (blue)
but significant conformational changes in the
loops.
(C) Zoom in view of the AA0 and GH loops shows
significant DcR3-dependent structural alterations.
See also Figure S8.
Structure
Structures of LIGHT and LIGHT:DcR3 Complex(SEC). Wild-type LIGHT and LIGHT mutants were qualitatively
evaluated for interactions with HVEM and LTbR by SEC. As
with wild-type LIGHT, significant peak shifts were observed
on mixing each mutant with DcR3, consistent with the mutants
retaining binding to DcR3 (Figure S7). However, when mixed
with HVEM, both mutants exhibited SEC traces differing from
the wild-type protein, consistent with impaired binding to
HVEM (Figure S7).
To more accurately quantify the interactions of the mutants
with DcR3-Ig, HVEM-Ig, and LTbR-Ig, surface plasmon reso-
nance (SPR) was used to measure equilibrium dissociation con-
stants (Kds). Mutant 1, which has the loop transplanted from the
lower interaction region, largely retains nearly wild-type binding
affinity to DcR3 (i.e., approximately 2-fold decrease in the affinity
comparing to wild-type LIGHT) (Table 2). However, mutant 2,
which has the loop transplanted from the upper region, exhibits
approximately 10-fold loss in affinity for DcR3 (Table 2). Mutant 1
and mutant 2 exhibited approximately 100-fold and 10-fold re-
ductions in affinity for HVEM, respectively, suggesting that the
GH loop may contribute more to the binding of HVEM than the
EF loop. Both mutants bound LTbR with affinities close to those
exhibited by the wild-type protein.
Crystal structures of LIGHT mutant 1 and mutant 2 bound to
DcR3 show that the interfaces and overall structural features
present in the wild-type structure are preserved in these com-
plexes (Table 1; Figure S1). In both LIGHT mutants, residue
Y173 occupies the hydrophobic groove of DcR3 and forms a
hydrogen bond with main chain of Q80 in a fashion indistinguish-
able from the wild-type LIGHT:DcR3 complex (Figure S3). In the
mutant 1 LIGHT:DcR3 complex, the binding pattern of the trans-
planted loop is very similar to that observed in the TL1A:DcR3
structure (PDB entry 3K51), in which the TL1A T239 (analogous
to LIGHT R228) carbonyl oxygen makes a main chain contact
with the DcR3 L94 amide nitrogen and TL1A E241 (analogous
to LIGHT G230) and DcR3 N92 side chains interact via hydrogen
bonding (Figure S4).
Like wild-type LIGHT and TL1A, DcR3-dependent conforma-
tional alterations were present in the analogous loops on LIGHT
mutant 2 (Figure S8). Notably, unlike mutant 1:DcR3 complex,
the transplanted loop inmutant 2 does not fully mimic the confor-
mation observed in the TL1A:DcR3 complex. Although the back-
bone of the transplanted loop in LIGHT mutant 2 superimposes
well with the same loop in TL1A, the side chains adopt different
conformations compared to TL1A (Figure S4).Structure 22, 1252–12Effects on Signaling
It has been reported that LIGHT-associated pathways inhibit
proliferation and trigger the apoptosis of HT-29 tumor cells,
possibly through engagement of HVEM and LTbR. To assess if
the altered binding affinities of the LIGHT mutants resulted in
different functional properties, we examined their effects over a
range of concentrations (0, 50 ng/ml, 100 ng/ml, or 200 ng/ml)
on HT-29 tumor cells. Our results show that wild-type LIGHT
induced apoptosis and reduced the viability of HT-29 cells in a
dose-dependent manner, reaching saturation at a concentration
of 100 ng/ml (Figure 6). Under the conditions used, 10% of
untreated HT-29 cells undergo apoptosis, while treatment with
wild-type LIGHT results in a 3-fold increase in apoptosis at the
concentration of 100 ng/ml. The two LIGHTmutants also elicited
dose-dependent effects; however, each mutant exhibited re-
duced activity, eliciting only a 2-fold increase in apoptosis
relative to the untreated cells at 100 ng/ml. Wild-type LIGHT
(100 ng/ml) decreases the viable cells of HT-29 to about 70%
of the control group. The mutant proteins exhibit reduced effects
on HT-29 cell viability (80% of control group) (Figure 6).
Since both mutants show little change in affinity for LTbR but
significant reductions in affinities for HVEM (100-fold reduction
for mutant 1 and 10-fold reduction for mutant 2), the reduced
induction of apoptosis and cell viability are likely the result of
impaired LIGHT:HVEM signaling. Although the two mutants
compromise the biological activities of LIGHT, at saturation,
the effect is incomplete, suggesting the involvement of
LIGHT:LTbR or other unknown LIGHT-related pathways.
Unusual Higher Order Assembly of the
LIGHT:DcR3 Complex
While the LIGHT:DcR3 complex described earlier is typical of the
TNF/TNFR superfamilies, crystal packing results in an unusual
dimer of heterohexamers. Two canonical LIGHT:DcR3 hexamers
form an interlocking assembly in which one hexamer is rotated
by 180 perpendicular to the 3-fold axis and rotated by 40 about
the 3-fold axis to form the dodecamer. Contacts between LIGHT
and DcR3 chains within the canonical hexamer are referred to as
‘‘cis’’ interactions, while contacts between the canonical hexam-
ers are termed ‘‘trans’’ interactions (Figure 7). The dodecamer is
stabilized by trans interactions between DcR3 CRD4 and the AA0
and DE loops of LIGHT, and by antiparallel trans contacts be-
tween two DcR3 molecules (Figure S9). No trans contacts occur
between the LIGHT trimers. The solvent-accessible surface area62, September 2, 2014 ª2014 Elsevier Ltd All rights reserved 1257
Figure 5. Rationale for Designing LIGHT Mutants
TL1A (red ribbon) and LIGHT (blue ribbon) both bind to DcR3; LIGHT also binds
HVEM and LTbR, while TL1A does not. Loop transplantation of the binding
sites from TL1A to LIGHT result in chimeric proteins which possess binding to
DcR3 but reduced interactions with HVEM and LTbR.
See also Figure S2.
Table 2. Binding Affinities of LIGHT with Receptors
Mutation Residues Kd (nM)
195–198 226–231 DcR3 HVEM LTbR
Wild-type RVWW RLRDGT 16.7 ± 0.3 18.7 ± 0.2 11.2 ± 0.6
Mutant 1 RVWW DYTKED 36.0 ± 1.8 2,500 ± 2,200 21.0 ± 3.3
Mutant 2 SNWF RLRDGT 153 ± 54 271 ± 37 17.2 ± 14
Structure
Structures of LIGHT and LIGHT:DcR3 Complexburied between each trans-interacting LIGHT and DcR3 is
560 A˚2 and involves hydrophobic interactions and hydrogen
bonds. The buried surface area associated with each DcR3-
DcR3 interaction is 460 A˚2 and includes many hydrogen bonds.1258 Structure 22, 1252–1262, September 2, 2014 ª2014 Elsevier LtTheN-linked glycan on N173 of DcR3 contacts the adjacent anti-
parallel DcR3 molecule, further stabilizing the assembly (Fig-
ure S9). The other potential N-linked glycan site is LIGHT
N102, which is not near the cis and trans interaction surfaces
and is thus unlikely to have an impact on the interactions be-
tween LIGHT and DcR3. The total buried solvent-accessible sur-
face area for the trans interaction is 5,300 A˚2, compared to
3,100 A˚2 for the total buried surface area associated with the
canonical 3:3 LIGHT-DcR3 cis interaction. It is interesting that
the structures of the LIGHT mutants in complex with DcR3
show crystal packing (i.e., the unusual dodecamer) similar to
the wild-type LIGHT:DcR3 complex, despite different crystalliza-
tion conditions (different pH, salt, and precipitants).
Although the structure of LIGHT:DcR3 suggests a model in
which the trans-interlocking dodecamer plays some biological
role, light scattering analysis shows that the LIGHT:DcR3 com-
plex exists as a single heterohexamer in solution (Figure S6).
Furthermore, we could not detect dodecameric interactions
involving cell-surface-expressed LIGHT and soluble DcR3.
Drosophila S2 cells were separately transfected with plasmids
encoding full-length LIGHT:red fluorophore (mCherry) fusions
or full-length LIGHT: green fluorophore (enhanced green fluores-
cent protein) fusions. Addition of the soluble DcR3 failed to direct
the formation of red:green cell conjugates (data not shown). This
behavior indicates that two interlocking hexamers are only
weakly associated and that the observed dodecamer may be
the consequence of crystal contacts.
DISCUSSION
We determined the crystal structures of LIGHT and the
LIGHT:DcR3 complex, as well as the structures of LIGHT mu-
tants in complex with DcR3. All of these structures exhibited
typical TNF/TNFR superfamily organization, with the receptor
binding along the length of the interprotomer interfaces of the
compact LIGHT trimer and a 3:3 receptor:ligand stoichiometry.
These structures revealed the chemical and physical determi-
nants specific for the LIGHT:DcR3 interaction and the mecha-
nisms contributing to the broad specificity of DcR3. Consistent
with the TL1A:DcR3 structure, CRD2 of DcR3 contributes the
major determinants for recognition of the lower region of LIGHT.
Despite the modest sequence identity between LIGHT and TL1A
(<35%), and the even greater divergence in the loop regions,
DcR3 utilizes the same surface for recognition of both ligands.
This broad specificity appears, at least in part, to be due to the
recognition of invariant main chain residues and conserved
side chains present in LIGHT, TL1A, and FasL.
As observed in the TL1A:DcR3 complex, the two parallel beta
sheets, which form the core of LIGHT, are insensitive to DcR3
binding, while the loops involved in DcR3 recognition exhibitd All rights reserved
Figure 6. Biological Activities of LIGHT on HT-29 Tumor Cells
(A) Fluorescence-activated cell sorting analysis of the apoptosis of HT-29 cells. The population of late apoptotic cells is indicated as propidium iodide and
annexin-V double-positive events in the upper right quadrant.
(B) The apoptosis percentages of HT-29 from different treatments (wild-type and mutants) at protein concentrations of 100 ng/ml. Stars indicate p values below
0.05% by paired t test; error bars are calculated from experiments performed in triplicate.
(C) The effect of different treatments on inhibition of HT-29 growth at protein concentrations of 100 ng/ml.
(D) The apoptosis percentage of HT-29 from treatments at different protein concentrations (0, 50, 100, and 200 ng/ml). Stars indicate p values below 0.05% by
paired t test; error bars are calculated from experiments performed in triplicate.
See also Figure S1.
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Structures of LIGHT and LIGHT:DcR3 Complexreceptor-dependent structural rearrangements. Determinants in
these loops are also involved in recognition of the cognate
signaling receptors for TL1A, LIGHT, and FasL. The segregation
of these determinants in relatively flexible and readily deformable
loop segments affords a facile mechanism for adoption of local
conformations required for each ligand to optimally engage
DcR3, as well as their cognate signaling receptors. In the upper
region of the interaction interface, flexibility between CRD2 and
CRD3 also contributes to the ability of DcR3 to recognize LIGHT,
TL1A, and FasL.
Based on these structures, two mutants of LIGHT were gener-
ated by transplanting loops from TL1A. Mutant 1 and mutant 2
exhibited 2-fold and 10-fold reductions, respectively, in affinities
for DcR3 relative to wild-type LIGHT. Both mutants show com-
promised binding (mutant 1 has 100-fold reduction and mutant
2 has 10-fold reduction) to HVEM but little difference in binding
to LTbR relative to wild-type LIGHT. The two loop transplant mu-
tants of LIGHT provide an opportunity to dissect the roles of
HVEM and LTbR in HT-29 biology. Our results show that both
mutants have compromised activities for inducing apoptosis
compared to wild-type LIGHT. We conclude the reduced
apoptosis effect is most likely the result of affinity reduction to
HVEM, indicating that interaction of LIGHT and HVEM plays a
role in HT-29 apoptosis.Structure 22, 1252–12Application of all crystallographic and noncrystallographic
symmetry (NCS) operators results in the formation of an inter-
locking dodecameric assembly, which was observed under a
number of distinct crystallization conditions (Figure S1). It is
interesting that the TNF:TNFR2 structure reported by (Mukai
et al., 2010) exhibits an arrangement of interlocking hexamers
similar to that observed in the LIGHT:DcR3 crystal structure (Fig-
ure 7). The overall structure of the LIGHT:DcR3 dodecamer is
more compact than that of the TNF:TNFR2 complex, as the dis-
tance between the centers of mass of the two LIGHT trimers is
59 A˚ compared to 68 A˚ for the two TNF trimers (Figure 7).
In addition, the receptors embracing the ligands are more con-
strained in the LIGHT:DcR3 complex than in the TNF:TNFR2
complex, with the C terminus of TNFR2 extending away from
the ligands (Figure 7). It was suggested that, since TNFR2 is a
membrane-anchored protein, the interlocking dodecamer
observed in the crystalline state would be inaccessible for
plasma membrane associated TNF and TNFR2; however, as
the TNF receptors can also exist as soluble species, these steric
constraints may be relaxed in certain circumstances (Mukai
et al., 2010; Spoettl et al., 2007). DcR3 exists solely as a soluble
molecule, obviating steric conflicts that might preclude forma-
tion of the interlocking assembly in vivo. It is interesting that a
natural variant of LIGHT, E214K, which is close to the trans62, September 2, 2014 ª2014 Elsevier Ltd All rights reserved 1259
Figure 7. LIGHT:DcR3 Forms Interlocking
Hexamers Similar to Those Observed in
TNF:TNFR2, PDB Entry 3ALQ
The ligands LIGHT and TNF are both shown as
surface representations. The receptors DcR3 and
TNFR2 are shown as ribbons.
(A) Side view of the LIGHT:DcR3 complex. For
clarity, one canonical LIGHT:DcR3 hexamer is
colored gray (LIGHT) and cyan (DcR3), and the
other is colored yellow (LIGHT) and orange (DcR3).
(B) Side view of the TNF:TNFR2 complex. For
clarity, one canonical TNF:TNFR2 hexamer is
colored light blue (TNF) and teal (TNFR2) and the
other is colored red (TNF) and salmon (TNFR2).
(C) Bottom view of the interlocking hexamers of
LIGHT:DcR3 complex.
(D) Boom view of the interlocking hexamers of the
TNF:TNFR2 complex.
See also Figure S6.
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Structures of LIGHT and LIGHT:DcR3 Complexinteraction interface (Figure S9), has been implicated in inflam-
matory diseases (Cheung et al., 2010). However, solution- and
cell-based studies failed to detect this higher order assembly,
and at present, no direct experimental evidence exists that sup-
ports a physiological role for the interlocking dodecamer.
In conclusion, we have determined the crystal structures of
LIGHT and the LIGHT:DcR3 complex that defined the determi-
nants responsible for the broad ligand recognition properties of
DcR3. Based on these structures, chimeric LIGHT molecules
were constructed that allowed for the biochemical and functional
dissection of LIGHT and provided insights into the roles of the
LIGHT:HVEM and LIGHT:LTbR interactions.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Human LIGHT and DcR3
LIGHT complementary DNA (cDNA) was synthesized commercially (Gen-
script). The extracellular domain (L83-V240) was cloned into the pMT/BiP/
V5-His A vector (Invitrogen) and cotransfected into Drosophila S2 cells with
the pCoBlast (Invitrogen) plasmid at a 20:1 ratio. A stable cell line was selected
with Blasticidin following the manufacture’s protocol (Invitrogen). LIGHT
expression was induced with copper sulfate (final concentration, 500 mM).
LIGHT protein from filtered culture supernatant was purified by nickel-nitrilo-
acetic acid column (QIAGEN) and SEC (HiLoad Superdex 75; Amersham).
The cloning, expression, and purification of DcR3 has been described else-
where (Zhan et al., 2011).
LIGHT mutants were generated by gene synthesis, and the corresponding
cDNAs were cloned into pET3a. All LIGHT mutants were expressed and re-
folded using published methods (Zhang et al., 2002). Briefly, LIGHT mutants
were expressed in E. coli and refolded from inclusion bodies and purified by
SEC using Superdex 200 gel-filtration columns.
Crystallization, Data Collection, and Structure Determination
LIGHT protein (10 mg/ml in HEPES, pH 7.0) was crystallized by sitting drop va-
por diffusion using 0.5 ml of protein and 0.5 ml of precipitant composed of
1.26 M monobasic sodium phosphate monohydrate, 0.14 M dibasic potas-
sium phosphate, and 10% (v/v) 0.2 M NDSB-211, pH 5.6, at 17C.
LIGHT:DcR3 complex (5 mg/ml in HEPES, pH 7.0) was crystallized by sitting
drop vapor diffusion by combining 0.5 ml of protein and 0.5 ml of precipitant
composed of 0.2 M sodium chloride, 0.1 M sodium citrate/citric acid buffer,
and 1.0 M dibasic ammonium phosphate, pH 5.5, at 17C. All crystals were
flash-cooled in mother liquor supplemented with 20% glycerol. LIGHT and
LIGHT:DcR3 crystals exhibited diffraction consistent with the space group
I212121 (94.69, 99.98, 124.38) and P213 (a = b = c = 149.06), respectively.1260 Structure 22, 1252–1262, September 2, 2014 ª2014 Elsevier LtAll mutant protein samples were crystallized by sitting drop vapor diffusion
by combining 0.5 ml of protein (5 mg/ml in HEPES, pH 7.0) and 0.5 ml of precip-
itant at 17C. The final crystallization conditions were as follows: LIGHTmutant
2, 0.2 M dibasic ammonium citrate, and 20% (w/v) polyethylene glycol 3350,
pH 5.0; mutant 1 LIGHT:DcR3 complex, 0.1 M imidazole-HCl, 2.5 M sodium
chloride, pH 8.0; mutant 2 LIGHT:DcR3, 0.2 M magnesium chloride, 0.1 M
Tris-HCl, 2.5 M sodium chloride, pH 7.0. LIGHT mutant 2 crystals were
flash-cooled and mounted directly. Crystals of mutant 1 LIGHT:DcR3 and
mutant 2 LIGHT:DcR3 complexes were mounted in mother liquor supple-
mented with 20% glycerol. LIGHT mutant 2 exhibited diffraction consistent
with space group P21 (a = 59.64, b = 46.91, c = 70.40, b = 98.02), and the
two mutant LIGHT:DcR3 complexes both exhibited diffraction consistent
with space group P213 (Mutant 1, a = b = c = 149.27; Mutant 2, a = b = c =
148.75).
All diffraction data were collected at beamline X29 of the National Synchro-
tron Light Source, Brookhaven National Laboratory. Data were integrated and
scaled with HKL2000 and further processed with the programs within the
CCP4 software package (Otwinowski and Minor, 1997; Winn et al., 2011).
The models were further built using Coot and refined by PHENIX or REFMAC5
(Adams et al., 2010; Emsley et al., 2010; Murshudov et al., 1997) without NCS
restraints. The figures in the article were generated using PyMOL (The PyMOL
Molecular Graphics System, Version 1.5.0.4, Schrodinger, LLC). The solvent-
accessible surface areas were calculated by online server PDBePISA, with a
probe radius of 1.4 A˚ (Krissinel and Henrick, 2007).
SEC-Multi-Angle Light Scattering
A solution of LIGHT and DCR3 (1 mg/ml) in buffer containing 20 mM HEPES,
150 mM NaCl, 1 mM EDTA, pH 7.5 or pH 5.5, was subjected to SEC using a
WTC030N5 column (Wyatt Technology Corporation) coupled to a Shimadzu
high-performance liquid chromatography system. LIGHT and DCR3 were
also mixed in molar ratios of 1:1, 2:1, and 1:2 and subjected to SEC-multiangle
light scattering (SEC-MALS). Light scattering measurements were performed
downstream, using a miniDawn TREOS instrument connected to the column
output, followed by Optilab rEX refractive index analysis (Wyatt Technology
Corporation). Control experiments were carried out with BSA diluted in the
same buffer as the sample. Data from these experiments were collected and
interpreted using ASTRA software (version 6.0.3.16).
SPR Binding Assay
The recombinant DcR3-Ig, HVEM-Ig, and LTbR-Ig were purchased from R&D
Systems and immobilized on a CM5 sensor chip (GE Life Sciences). The bind-
ing of soluble wild-type and mutant LIGHTs to these receptors was examined
at 25C using a BIAcore 3000 optical biosensor. The wild-type and mutants of
LIGHT were injected and flowed over the chip at concentrations ranging from
3 nM to 0.3 mM at a flow rate of 20 ml/min. The signals derived from different
concentration were corrected with the response of the blank channel (nod All rights reserved
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Structures of LIGHT and LIGHT:DcR3 Complexprotein immobilized in the channel). The resulting data were plotted and
analyzed with Prism 5 (Graphpad Software) using the one site-total model
[equation: Y = Bmax , X/ (Kd + X); Bmax: maximum specific binding].
Biological Activity Assay
HT-29 cells (0.5 3 106) were cultured in six-well plates with 10% fetal bovine
serum and Dulbecco’s modified Eagle’s medium. Cells were cultured over-
night and treated with (0 ng/ml, 50 ng/ml, 100 ng/ml, or 200 ng/ml) purified
LIGHT or LIGHT mutants for 72 hr. The endotoxin level in all protein samples
was less than 0.25 endotoxin units per milliliter, as determined by the Limulus
amebocyte lysate method (GenScript Endotoxin Assay Kit). The numbers of
live cells in each treatment were determined by the trypan blue exclusion
method (Zhai et al., 1998). The cells were also analyzed by Annexin-V staining
(BD PharMingen) to measure apoptosis (Zhai et al., 1998). Briefly, HT-29 cells
were washed twice with cold PBS and resuspended in binding buffer to a con-
centration of approximately 1 3 106 cells per milliliter. Resuspended cells
(100 ml) were mixed with 5 ml of Annexin V and 5 ml of propidium iodide. After
gentle mixing and incubation for 15 min at room temperature in the dark,
400 ml of binding buffer was added, and the samples were subjected to flow
cytometry analysis. The experiments are performed in triplicate, and the signif-
icance of the resulting data was evaluated by the paired t test.
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